Results

Total Results: 2,432 records

Showing results for "risk".

1. Archived: Postmenopausal Hormone Replacement Therapy for Primary Prevention of Chronic Conditions: Evidence Summary: Menopausal Hormone Therapy: Preventive Medication, 2002 and 2005 | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/postmenopausal-hormone-replacement-therapy-for-primary-preve/v2-menopausal-hormone-therapy-preventive-medicatio
   August 21, 2002 - studies including three meta-analyses (relative risks range from 1.21 to 1.40). 71-73 Risk increases … with longer duration of use (relative risks range from 1.23 to 1.35 based on all six meta-analyses that … for breast cancer (relative risks range from 0.85 to 1.14 from 8 meta-analyses). 40 , 71-77 No meta-analyses … Except for CHD, rates are similar when WHI hazard ratios rather than relative risks from our review are … In many cases, a variety of relative risks was available for certain outcomes, and we selected a value

2. Archived: Postmenopausal Hormone Replacement Therapy for Primary Prevention of Chronic Conditions: Evidence Summary: Menopausal Hormone Therapy: Preventive Medication, 2002 and 2005 | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/postmenopausal-hormone-replacement-therapy-for-primary-preve/menopausal-hormone-therapy-preventive-medication-2002-2005
   August 21, 2002 - studies including three meta-analyses (relative risks range from 1.21 to 1.40). 71-73 Risk increases … with longer duration of use (relative risks range from 1.23 to 1.35 based on all six meta-analyses that … for breast cancer (relative risks range from 0.85 to 1.14 from 8 meta-analyses). 40 , 71-77 No meta-analyses … Except for CHD, rates are similar when WHI hazard ratios rather than relative risks from our review are … In many cases, a variety of relative risks was available for certain outcomes, and we selected a value

3. Postmenopausal Hormone Replacement Therapy for the Primary Prevention of Chronic Conditions: A Summary of the Evidence for the USPSTF (pdf file)
   www.uspreventiveservicestaskforce.org/home/getfilebytoken/sQ7hREGwnBm8Wh-LEFWP4F
   October 01, 2002 - studies including 3 meta- analyses (relative risks range from 1.21 to 1.40).71-73 Risk increases with … longer duration of use (relative risks range from 1.23 to 1.35 based on all 6 meta- Postmenopausal … for breast cancer (relative risks range from 0.85 to 1.14 from 8 meta-analyses).40,71-77 No meta-analyses … Except for CHD, rates are similar when WHI hazard ratios rather than relative risks from our review are … In many cases, a variety of relative risks was available for certain outcomes, and we selected a value

4. Archived: Evidence Summary: Breast Cancer: Medications for Risk Reduction | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/v1-breast-cancer-medications-for-risk-reduction--s
   May 06, 2002 - The relative risk reduction was similar across all age groups and all risk levels. … was concentrated in women ages 50 and older; the relative risks for women younger than age 50 were smaller … for recruitment into the study. 40 Given a constant relative risk reduction across breast cancer risk … and the relative risk by which the baseline risk is multiplied for tamoxifen users. … ‡HR, hazard ratio, the estimate of relative risk at a given time.

5. Archived: Evidence Summary: Breast Cancer: Medications for Risk Reduction | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary/breast-cancer-medications-for-risk-reduction-2002
   May 06, 2002 - The relative risk reduction was similar across all age groups and all risk levels. … was concentrated in women ages 50 and older; the relative risks for women younger than age 50 were smaller … for recruitment into the study. 40 Given a constant relative risk reduction across breast cancer risk … and the relative risk by which the baseline risk is multiplied for tamoxifen users. … ‡HR, hazard ratio, the estimate of relative risk at a given time.

6. Archived: Evidence Summary: NSAIDs: Aspirin/NSAIDs for Prevention of Colorectal Cancer: Preventive Medication | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary-nsaids/aspirin-nsaids-for-prevention-of-colorectal-cancer-preventive-medication
   March 15, 2007 - Confounders Addressed in Adjusted Relative Risks among the Included Case-Control Studies: Use of Nonaspirin … Confounders Addressed in Adjusted Relative Risks among the Included Case-Control Studies: Duration of … We chose relative risk as the effect measure. … Confounders Addressed in Adjusted Relative Risks among the Included Case-Control Studies: Use of Nonaspirin … Confounders Addressed in Adjusted Relative Risks among the Included Case-Control Studies: Duration of

7. Archived: Coronary Heart Disease: Screening Using Non-Traditional Risk Factors | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/recommendation/coronary-heart-disease-screening-using-non-traditional-risk-factors-2009
   October 15, 2009 - significant relative risks that ranged from 1.36 to 1.90. … factors in asymptomatic persons (1300 to 16 000 men and women who showed a relative risk of 1.19 to … In summary, although the 8 included studies consistently reported statistically significant relative … risks for coronary events with increasing CAC scores, no study uniformly met all 3 of the following conditions … risk variables (including diabetes), the summary estimate of relative risk for incident CHD was 1.58

8. Archived: Coronary Heart Disease: Screening Using Non-Traditional Risk Factors | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/recommendation/coronary-heart-disease-screening-using-non-traditional-risk-factors
   October 15, 2009 - significant relative risks that ranged from 1.36 to 1.90. … factors in asymptomatic persons (1300 to 16 000 men and women who showed a relative risk of 1.19 to … In summary, although the 8 included studies consistently reported statistically significant relative … risks for coronary events with increasing CAC scores, no study uniformly met all 3 of the following conditions … risk variables (including diabetes), the summary estimate of relative risk for incident CHD was 1.58

9. Archived: Evidence Summary: NSAIDs: Aspirin/NSAIDs for Prevention of Colorectal Cancer: Preventive Medication | United States Preventive Services Taskforce
   www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary-nsaids/aspirin-nsaids-for-prevention-of-colorectal-cancer-preventive-medication-2007
   March 15, 2007 - Confounders Addressed in Adjusted Relative Risks among the Included Case-Control Studies: Use of Nonaspirin … Confounders Addressed in Adjusted Relative Risks among the Included Case-Control Studies: Duration of … We chose relative risk as the effect measure. … Confounders Addressed in Adjusted Relative Risks among the Included Case-Control Studies: Use of Nonaspirin … Confounders Addressed in Adjusted Relative Risks among the Included Case-Control Studies: Duration of

10. Screening for Asymptomatic Coronary Artery Disease: Systematic Evidence Review (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/-XKf9dRtb-S6oSsBzwsCdw
    December 08, 2003 - in the relative risk for CHD events of 1.7 to 4.0. … after adjustment for other CHD risk factors (relative risks 1.7 to 3.2). … Risks for CHD Mortality (95% CI) Relative Risk Adjusted for the Following Variables Pedoe … Risks for CHD Mortality (95% CI) Relative Risk Adjusted for the Following Variables Kahn et … Risks for CHD Mortality (95% CI) Relative Risk Adjusted for the Following Variables Jones

11. Nonsteroidal Anti-inflammatory Drugs and Cyclooxygenase-2 Inhibitors for Primary Prevention of Colorectal Cancer: A Systematic Review (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/EppFbhnDEX5UtYWrTkLEhT
    March 01, 2007 - We chose relative risk as the effect measure. … We directly abstracted point esti- mates of the adjusted relative risks and their 95% CIs from the reports … NSAIDs [54]; 1.43 (0.99–2.07) for rofecoxib vs. celecoxib [58] * Data reported are relative risks (95% … Confounders Addressed in Adjusted Relative Risks among the Included Case–Control Studies: Use of Nonaspirin … Confounders Addressed in Adjusted Relative Risks among the Included Case–Control Studies: Duration of

12. Modeling Study: Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/final-modeling-study/aspirin-to-prevent-cardiovascular-disease-preventive-medication
    April 26, 2022 - In all scenarios, non-CRC benefits and harms were assumed to take effect immediately, and relative risks … estimate was lower and had a narrower confidence interval compared with the corresponding finding in 2016 (relative … for CRC incidence and affects fatal major gastrointestinal bleeding risks. … constant over time, but lifetime net benefits of aspirin would be higher if these relative risks decreased … CVD Parameter Relative

13. Chemo and Couns/2nd instal (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/-hnLT26c2NHs6thK9yznPF
    July 01, 2002 - The relative risk reduction was similar across all age groups and all risk levels. … was concentrated in women aged 50 and older; the relative risks for women younger than age 50 were smaller … Considerations of Risk of Developing Breast Cancer The relative risk reduction for estrogen receptor … for recruitment into the study.40 Given a constant relative risk reduction across breast cancer risk … and the relative risk by which the baseline risk is multiplied for tamoxifen users.

14. Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/3HxQuXnyqHpUKNqjB7hWBw
    September 01, 2005 - risks for breast and ovarian cancer in moderate- and high-risk groups. … All chemoprevention trials reported relative risk (RR) estimates, and the logarithm of the RR (logRR) … Combining all trials in a meta-analysis resulted in a relative risk for total breast cancer of 0.62 ( … The relative risk (0.39 [CI, 0.20 to 0.79]) was further reduced for estrogen receptor–positive breast … Relative risks for breast cancer in chemoprevention trials.

15. Using Aspirin for the Primary Prevention of Cardiovascular Disease (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/4fdC2JLwP_um_yZe4WZRaa
    April 01, 2009 - prevention studies of aspirin have found the following: Clinician Fact Sheet Aspirin use in women y 17% relative … relative risk reduction for MI y No effect on stroke or all-cause mortality y Talk With Your … Harms from aspirin include the risks of serious upper GI bleeding and hemorrhagic stroke. … this risk in women. … For these individuals, the benefits and risks of using aspirin are closely balanced.

16. Archived: Evidence Summary: Hepatitis B Virus Infection: Screening, 2014 | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary29/hepatitis-b-virus-infection-screening-may-2014
    May 27, 2014 - For antiviral therapy and vaccination, we conducted meta-analyses to calculate relative risks using the … For antiviral therapy and vaccination, we conducted meta-analyses to calculate relative risks using the … There are 2 studies comparing adefovir and placebo, with a pooled relative risk of 2.02 and 95% CI of … Two studies had no incidence of mortality in either group, resulting in relative risks that were not … In the third study, the relative risk was 1.48 with a 95% CI of 0.48 to 4.53.

17. Archived: Evidence Summary: Hepatitis B Virus Infection: Screening, 2014 | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary29/hepatitis-b-virus-infection-screening-nonpregnant-adolescents-adults-may-2014
    May 27, 2014 - For antiviral therapy and vaccination, we conducted meta-analyses to calculate relative risks using the … For antiviral therapy and vaccination, we conducted meta-analyses to calculate relative risks using the … There are 2 studies comparing adefovir and placebo, with a pooled relative risk of 2.02 and 95% CI of … Two studies had no incidence of mortality in either group, resulting in relative risks that were not … In the third study, the relative risk was 1.48 with a 95% CI of 0.48 to 4.53.

18. Evidence Summary: Bleeding Risks With Aspirin Use: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary-bleeding-risks-with-aspirin-use/aspirin-to-prevent-cardiovascular-disease-and-cancer
    April 11, 2016 - outcome, we calculated a range of expected event rates after aspirin intervention using the pooled relative … events will vary depending on individual baseline bleeding risks. … why persons with these risks have been excluded from trials. … Level † Baseline Risk for Outcome, events per 1000 person-years Relative Risk (95% CI) Events … ¶ Using cohort baseline risk and trial relative risks to estimate events caused or prevented.

19. Archived: Evidence Summary: Bleeding Risks With Aspirin Use: Aspirin Use to Prevent Cardiovascular Disease and Colorectal Cancer: Preventive Medication | United States Preventive Services Taskforce
    www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary-bleeding-risks-with-aspirin-use/aspirin-to-prevent-cardiovascular-disease-and-cancer-april-2016
    April 11, 2016 - outcome, we calculated a range of expected event rates after aspirin intervention using the pooled relative … events will vary depending on individual baseline bleeding risks. … why persons with these risks have been excluded from trials. … Level † Baseline Risk for Outcome, events per 1000 person-years Relative Risk (95% CI) Events … ¶ Using cohort baseline risk and trial relative risks to estimate events caused or prevented.

20. Using Nontraditional Risk Factors in Coronary Heart Disease Risk Assessment: U.S. Preventive Services Task Force Recommendation Statement (pdf file)
    www.uspreventiveservicestaskforce.org/home/getfilebytoken/gXnmnkofo8FxoLnCmXJDjb
    October 01, 2009 - sig- nificant relative risks that ranged from 1.36 to 1.90. … fac- tors in asymptomatic persons (1300 to 16 000 men and women who showed a relative risk of 1.19 … In summary, although the 8 included studies consis- tently reported statistically significant relative … risks for cor- onary events with increasing CAC scores, no study uni- formly met all 3 of the following … of relative risk for incident CHD was 1.58 (CI, 1.37 to 1.83) for an hs-CRP level greater than 3.0 mg